EARTH Study Rosuvastatin Dr Karnik
0 likes167 views
This study evaluated the efficacy and safety of rosuvastatin 40mg treatment in patients at high risk of cardiovascular events due to dyslipidemia. Rosuvastatin significantly reduced LDL cholesterol levels and other lipid parameters compared to placebo. Adverse events were mild to moderate in severity and consistent with the known safety profile of rosuvastatin.
EARTH Study Rosuvastatin Dr Karnik
- 1. Efficacy Evaluation and Safety Assessment of Rosuvastatin 40mg Treatment in High Risk Dyslipidemic Patients (Earth Study)